MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer

被引：0
|
作者：
Sung Hwan Lee
Ho Kyoung Hwang
Woo Jung Lee
Chang Moo Kang
机构：
[1] CHA Bundang Medical Center,Department of Surgery
[2] CHA University School of Medicine,Laboratory of HBP Integrative Precision Oncology
[3] CHA Bio Complex,Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery
[4] CHA Health System,Pancreatobiliary Cancer Center
[5] Yonsei University College of Medicine,undefined
[6] Yonsei Cancer Center,undefined
[7] Severance Hospital,undefined
来源：
Cellular Oncology | 2021年 / 44卷
关键词：
Pancreatic cancer; MCT4; Gemcitabine; Chemotherapy; Pancreatectomy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1363 / 1371
页数：8
相关论文
共 50 条
  • [31] Monocarboxylate Transporter 4 (MCT4) Knockout Mice Have Attenuated 4NQO Induced Carcinogenesis; A Role for MCT4 in Driving Oral Squamous Cell Cancer
    Bisetto, Sara
    Whitaker-Menezes, Diana
    Wilski, Nicole A.
    Tuluc, Madalina
    Curry, Joseph
    Zhan, Tingting
    Snyder, Christopher M.
    Martinez-Outschoorn, Ubaldo E.
    Philp, Nancy J.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [32] Blocking MCT4 SUMOylation inhibits the growth of breast cancer cells
    Hu, Xiao
    Liu, Zhanzhao
    Duan, Xianxian
    Han, Xiao
    Yuan, Mengci
    Liu, Lingyan
    Xia, Xiaojun
    Li, Ning
    Qin, Junfang
    Wang, Yue
    MOLECULAR CARCINOGENESIS, 2021, 60 (10) : 702 - 714
  • [33] MCT INHIBITION AS A POTENTIAL THERAPEUTIC STRATEGY TO TARGET ENZALUTAMIDE-RESISTANT PROSTATE CANCER
    Bhattacharjee, Sayani
    Doan, Jonathan P.
    Pletcher, Jerred P.
    Wynn, Rebecca
    Petros, Firas
    Sindhwani, Puneet
    Nadiminty, Nagalakshmi
    JOURNAL OF UROLOGY, 2020, 203 : E767 - E767
  • [34] The circadian clock as a potential biomarker and therapeutic target in pancreatic cancer
    Pourali, Ghazaleh
    Ahmadzade, Amir Mahmoud
    Arastonejad, Mahshid
    Pourali, Roozbeh
    Kazemi, Danial
    Ghasemirad, Hamidreza
    Khazaei, Majid
    Fiuji, Hamid
    Nassiri, Mohammadreza
    Hassanian, Seyed Mahdi
    Ferns, Gordon A.
    Avan, Amir
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2024, 479 (05) : 1243 - 1255
  • [35] Hepatocyte Growth Factor: A Potential Therapeutic Target in Pancreatic Cancer
    Arun, S. J.
    Xu, Z.
    Fiala-Beer, E.
    Yang, L.
    Phillips, P. A.
    Goldstein, D.
    Biankin, A.
    Pirola, R.
    Wilson, J. S.
    Apte, M. V.
    PANCREAS, 2011, 40 (08) : 1310 - 1311
  • [36] ROCK1 as a potential therapeutic target in pancreatic cancer
    Whatcott, Clifford
    Watanabe, Aprill
    Demirjian, Joseph
    Barrett, Michael
    Hostetter, Galen
    Von Hoff, Daniel
    Han, Haiyong
    CANCER RESEARCH, 2011, 71
  • [37] Hepatocyte growth factor: a potential therapeutic target in pancreatic cancer
    Arun, S. J.
    Xu, Z.
    Fiala-Beer, E.
    Phillips, P.
    Goldstein, D.
    Biankin, A.
    Pirola, R.
    Wilson, J. S.
    Apte, M. V.
    CANCER RESEARCH, 2011, 71
  • [38] CRM-1 as a potential therapeutic target in pancreatic cancer
    Azmi, Asfar S.
    McCauley, Dilara
    Shacham, Sharon
    Kauffman, Michael
    Mohammad, Ramzi M.
    CANCER RESEARCH, 2012, 72
  • [39] Survivin is a Potential New Therapeutic Target in the Treatment of Pancreatic Cancer
    Ly, Q. P.
    Howell, G.
    Mendick, M.
    Murari, C.
    Laschanzky, S.
    Brattain, M.
    PANCREAS, 2015, 44 (08) : 1394 - 1395
  • [40] Histamine receptor 1: A potential therapeutic target for pancreatic cancer
    Bort, Elena Tomas
    Salvador, Cristina Salmeron
    Sriram, Krishna
    Javadi-Paydar, Mehrak
    Smitham, Jane
    Grose, Richard
    McCormick, Peter
    Insel, Paul
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 (04) : 567 - 567
12345